Dr. Reddy's Laboratories Receives Health Canada Approval for Generic Semaglutide Injection

Dr. Reddy's Laboratories Limited has received a Notice of Compliance (NOC) from Health Canada for its Abbreviated New Drug Submission (ANDS) of Semaglutide Injection. This approval makes Dr. Reddy's the first company to receive marketing authorization for generic Semaglutide Injection in Canada. The NOC authorizes the commercialization, sale, and distribution of the drug in Canada. Semaglutide Injection is indicated for the once-weekly treatment of adult patients with type 2 diabetes to improve glycemic control. This approval highlights Dr. Reddy's expertise in complex generics and peptide-based therapeutics, with in-house API production and manufacturing by a partner. The company is preparing for the launch of the product in Canada, a significant market for Semaglutide. This development is a key milestone in Dr. Reddy's GLP-1 portfolio and reinforces its commitment to providing access to affordable and innovative diabetes treatments.